What to do with an abnormal PSA test
- PMID: 18378540
- DOI: 10.1634/theoncologist.2007-0139
What to do with an abnormal PSA test
Abstract
For more than a decade, prostate-specific antigen (PSA) has been used for prostate cancer screening. Over the years, this screening has been continually refined, including investigation into the use of lower total PSA thresholds, PSA isoforms, and PSA kinetics. This review describes the evolution of prostate cancer screening and provides clinical insights into the informed use of PSA and its adjunctive measurements.
Comment in
-
Commentary: how serious is getting a diagnosis of prostate cancer?Oncologist. 2008 Mar;13(3):306-8. doi: 10.1634/theoncologist.2008-0008. Oncologist. 2008. PMID: 18378541 No abstract available.
Similar articles
-
An evaluation of prostate-specific antigen as a screening test for prostate cancer.Arch Intern Med. 1993 Nov 22;153(22):2529-37. Arch Intern Med. 1993. PMID: 7694555 Review.
-
Promoting prostate-specific antigen informed decision-making. Evaluating two community-level interventions.Am J Prev Med. 2008 Aug;35(2):87-94. doi: 10.1016/j.amepre.2008.04.016. Am J Prev Med. 2008. PMID: 18617077 Clinical Trial.
-
[Results and participation factors to the European Randomized study of Screening for Prostate Cancer (ERSPC) with Prostate Specific Antigen: French departments of Tarn and Hérault].Prog Urol. 2009 Jul;19(7):487-98. doi: 10.1016/j.purol.2009.03.001. Epub 2009 Apr 28. Prog Urol. 2009. PMID: 19559380 Clinical Trial. French.
-
The effect of obesity and lower serum prostate-specific antigen levels on prostate-cancer screening results in American men.BJU Int. 2009 Nov;104(10):1457-61. doi: 10.1111/j.1464-410X.2009.08646.x. Epub 2009 Jun 12. BJU Int. 2009. PMID: 19522868
-
Prostate-specific antigen kinetics in localized and advanced prostate cancer.BJU Int. 2009 Mar;103(5):578-87. doi: 10.1111/j.1464-410X.2009.08345.x. Epub 2009 Feb 6. BJU Int. 2009. PMID: 19210674 Review.
Cited by
-
Combinations of serum prostate-specific antigen and plasma expression levels of let-7c, miR-30c, miR-141, and miR-375 as potential better diagnostic biomarkers for prostate cancer.DNA Cell Biol. 2015 Mar;34(3):189-200. doi: 10.1089/dna.2014.2663. Epub 2014 Dec 18. DNA Cell Biol. 2015. PMID: 25521481 Free PMC article.
-
Pathologic characteristics of cancers detected in The Prostate Cancer Prevention Trial: implications for prostate cancer detection and chemoprevention.Cancer Prev Res (Phila). 2008 Aug;1(3):167-73. doi: 10.1158/1940-6207.CAPR-08-0078. Epub 2008 May 18. Cancer Prev Res (Phila). 2008. PMID: 19138952 Free PMC article. Clinical Trial.
-
Carbonic anhydrase I as a new plasma biomarker for prostate cancer.ISRN Oncol. 2012;2012:768190. doi: 10.5402/2012/768190. Epub 2012 Nov 19. ISRN Oncol. 2012. PMID: 23213568 Free PMC article.
-
Doctors' approaches to PSA testing and overdiagnosis in primary healthcare: a qualitative study.BMJ Open. 2015 Mar 17;5(3):e006367. doi: 10.1136/bmjopen-2014-006367. BMJ Open. 2015. PMID: 25783420 Free PMC article.
-
Highly efficient capture and enumeration of low abundance prostate cancer cells using prostate-specific membrane antigen aptamers immobilized to a polymeric microfluidic device.Electrophoresis. 2009 Sep;30(18):3289-300. doi: 10.1002/elps.200900141. Electrophoresis. 2009. PMID: 19722212 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous